Menu
Currency
GWAS Study

Shared genetic risk factors across carbamazepine-induced hypersensitivity reactions.

Nicoletti P, Barrett S, McEvoy L et al.

31066027 PubMed ID
GWAS Study Type
8450 Participants
35 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

NP
Nicoletti P
BS
Barrett S
ML
McEvoy L
DA
Daly AK
AG
Aithal G
LM
Lucena MI
AR
Andrade RJ
WM
Wadelius M
HP
Hallberg P
SC
Stephens C
BE
Bjornsson ES
FP
Friedmann P
KK
Kainu K
LT
Laitinen T
MA
Marson A
MM
Molokhia M
PE
Phillips E
PW
Pichler W
RA
Romano A
SN
Shear N
SG
Sills G
TL
Tanno LK
SA
Swale A
FA
Floratos A
SY
Shen Y
NM
Nelson MR
WP
Watkins PB
DM
Daly MJ
MA
Morris AP
AA
Alfirevic A
PM
Pirmohamed M
Chapter II

Abstract

Summary of the research findings

Carbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI). In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-analysis of two genomewide association studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls. HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10-9 ) and CBZ-DILI (OR = 7.3; 95% CI 2.47-23.67; P = 0.0004) in European populations. The association with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10-9 ) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an association with HLA-B*57:01. We also identified a novel risk locus mapping to ALK only for CBZ-SCAR cases, which needs replication in additional cohorts and functional evaluation.

12 European ancestry cases, 8,438 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

8450
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.K.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.